ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has appointed PAREXEL International Corp. to develop, coordinate and prepare the New Drug Application (NDA) and the European Marketing Authorization Application (MAA) for Valeant’s investigational compound retigabine. Retigabine is a novel neuronal potassium-channel opener that is being studied in Phase 3 clinical trials as an adjunctive treatment for partial-onset seizures in patients with epilepsy. Valeant anticipates filing the NDA and MAA for retigabine in mid-2008.
